Pharmacokinetic and Pharmacodynamic Properties of Single- and Multiple-Dose of Dapagliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects

Yang Li(University of Cambridge), David W. Boulton(AstraZeneca (Poland)), Sreeneeranj Kasichayanula(Gilead Sciences (United States)), Anh Thi Ngoc Bui(Bristol-Myers Squibb (United States)), Frank LaCreta(Fox Chase Cancer Center), Haiyan Li(Peking University), Hongmei Li(Guizhou Provincial People's Hospital), Steven C. Griffen(Io Therapeutics (United States)), Xiaoni Liu(Bristol-Myers Squibb (Germany)), Ming Chang
Clinical Therapeutics
August 1, 2013
Cited by 43


Related Papers